Kyowa Kirin Co., Ltd. (KYKOF)

17,33 0,00 (0,00%) In data: 01:51PM EDT. Mercato aperto.

Kyowa Kirin Co., Ltd.

Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
https://www.kyowakirin.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 5.974

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Masashi Miyamoto Ph.D.	President, CEO & Representative Director	829,82k	N/D	1959
Mr. Motohiko Kawaguchi	CFO, Managing Executive Officer & Head of Global Finance	N/D	N/D	N/D
Mr. Yutaka Osawa M.B.A.	CCO, Executive VP & Representative Director	505,67k	N/D	1959
Kazuki Nemoto	Head of Global Legal	N/D	N/D	N/D
Hiroki Nakamura	Global Corporate Communications Head	N/D	N/D	N/D
Hiroshi Sonekawa	Managing Executive Officer, VP and Head of Sales & Marketing Division	N/D	N/D	N/D
Wataru Murata M.B.A.	Chief People Officer & Head of Global Human Resources	N/D	N/D	N/D
Mr. Takeyoshi Yamashita Ph.D.	Chief Medical Officer, Senior Managing Executive Officer & Director	N/D	N/D	1961
Yasuo Fujii M.B.A.	Chief Strategy Officer, VP & Managing Executive Officer	N/D	N/D	N/D
Jean-David Rafizadeh-Kabe J.D., M.D.	Head of Global Operational Transformation	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Governance aziendale

L'ISS Governance QualityScore di Kyowa Kirin Co., Ltd. al 1 maggio 2024 è 1. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 1; diritti degli azionisti: 4; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.